Dual-Gated Motion-Frozen Cardiac PET with Flurpiridaz F 18
Overview
Authors
Affiliations
Unlabelled: A novel PET radiotracer, Flurpiridaz F 18, has undergone phase II clinical trial evaluation as a high-resolution PET cardiac perfusion imaging agent. In a subgroup of patients imaged with this agent, we assessed the feasibility and benefit of simultaneous correction of respiratory and cardiac motion.
Methods: In 16 patients, PET imaging was performed on a 4-ring scanner in dual cardiac and respiratory gating mode. Four sets of data were reconstructed with high-definition reconstruction (HD•PET): ungated and 8-bin electrocardiography-gated images using 5-min acquisition, optimal respiratory gating (ORG)-as developed for oncologic imaging-using a narrow range of breathing amplitude around end-expiration level with 35% of the counts in a 7-min acquisition, and 4-bin respiration-gated and 8-bin electrocardiography-gated images (32 bins in total) using the 7-min acquisition (dual-gating, using all data). Motion-frozen (MF) registration algorithms were applied to electrocardiography-gated and dual-gated data, creating cardiac-MF and dual-MF images. We computed wall thickness, wall/cavity contrast, and contrast-to-noise ratio for standard, ORG, cardiac-MF, and dual-MF images to assess image quality.
Results: The wall/cavity contrast was similar for ungated (9.3 ± 2.9) and ORG (9.5 ± 3.2) images and improved for cardiac-MF (10.8 ± 3.6) and dual-MF images (14.8 ± 8.0) (P < 0.05). The contrast-to-noise ratio was 22.2 ± 9.1 with ungated, 24.7 ± 12.2 with ORG, 35.5 ± 12.8 with cardiac-MF, and 42.1 ± 13.2 with dual-MF images (all P < 0.05). The wall thickness was significantly decreased (P < 0.05) with dual-MF (11.6 ± 1.9 mm) compared with ungated (13.9 ± 2.8 mm), ORG (13.1 ± 2.9 mm), and cardiac-MF images (12.1 ± 2.7 mm).
Conclusion: Dual (respiratory/cardiac)-gated perfusion imaging with Flurpiridaz F 18 is feasible and improves image resolution, contrast, and contrast-to-noise ratio when MF registration methods are applied.
Motion-correction strategies for enhancing whole-body PET imaging.
Wang J, Bermudez D, Chen W, Durgavarjhula D, Randell C, Uyanik M Front Nucl Med. 2024; 4.
PMID: 39118964 PMC: 11308502. DOI: 10.3389/fnume.2024.1257880.
Lassen M, Rasmussen T, Byrne C, Holmvang L, Kjaer A, Hasbak P J Nucl Cardiol. 2023; 30(6):2289-2300.
PMID: 37624562 PMC: 10682154. DOI: 10.1007/s12350-023-03360-x.
Motion correction for diagnosis of cardiac sarcoidosis-do we have all the answers?.
Hossen L, Wechalekar K J Nucl Cardiol. 2023; 30(5):1886-1889.
PMID: 37491509 DOI: 10.1007/s12350-023-03330-3.
F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation.
Grkovski M, Zanzonico P, Modak S, Humm J, Narula J, Pandit-Taskar N J Nucl Cardiol. 2022; 29(6):3179-3188.
PMID: 34993893 PMC: 10155237. DOI: 10.1007/s12350-021-02813-5.
Schultz J, Siekkinen R, Jafari Tadi M, Teras M, Klen R, Lehtonen E J Nucl Cardiol. 2021; 29(5):2423-2433.
PMID: 34476780 PMC: 9553777. DOI: 10.1007/s12350-021-02769-6.